title: Treatment of cytomegalovirus pneumonia in heart transplant recipients with 9(1,3-dihydroxy-2-proproxymethyl)-guanine (DHPG).
abstract: Cytomegalovirus (CMV) infection is a frequent cause of serious illness in heart transplant patients and may cause life-threatening pneumonia, with a reported mortality of greater than 50%. We investigated the clinical efficacy of a new antiviral agent, 9(1,3-dihydroxy-2-proproxymethyl)-guanine (DHPG) in the treatment of CMV pneumonia in heart transplant patients. Four of these patients with biopsy-proved CMV pneumonia were treated with DHPG, with resolution of pneumonia and no relapse at a mean follow-up period of 21 weeks. DHPG may be useful in the treatment of CMV pneumonia in heart transplant patients.
authors.affiliation: Division of Cardiology, University of Utah Medical Center, Salt Lake City 84132.
authors.forename: F S
authors.initials: FS
authors.lastname: Watson
authors.forename: J B
authors.initials: JB
authors.lastname: O'Connell
authors.forename: I J
authors.initials: IJ
authors.lastname: Amber
authors.forename: D G
authors.initials: DG
authors.lastname: Renlund
authors.forename: D
authors.initials: D
authors.lastname: Classen
authors.forename: J M
authors.initials: JM
authors.lastname: Johnston
authors.forename: C B
authors.initials: CB
authors.lastname: Smith
authors.forename: M R
authors.initials: MR
authors.lastname: Bristow
mesh_terms: D000212:Acyclovir / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000209:etiology; D015774:Ganciclovir; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011024:Pneumonia, Viral / Q000188:drug therapy* / Q000209:etiology
chemical_list: D007166:Immunosuppressive Agents; D015774:Ganciclovir; D000212:Acyclovir